RNS Number : 5821J Unilever PLC 21 May 2025

PUBLICATION OF FINAL TERMS

London, 21 May 2025.

The following final terms (the "Final Terms") are available for viewing:

- (i) the Final Terms dated 20 May 2025 for Unilever Capital Corporation ¹ EUR 700,000,000 2.750 per cent. Notes due 22 May 2030 (the "2030 Notes"); and
- (ii) the Final Terms dated 20 May 2025 for Unilever Capital Corporation EUR 800,000,000 3.375 per cent. Notes due 22 May 2035 (together with the 2030 Notes, the "**Notes**"),

each guaranteed by Unilever PLC^2 and Unilever United States, $Inc.^3$ and issued under the 25,000,000,000 Debt Issuance Programme of Unilever Finance Netherlands B.V., Unilever PLC and Unilever Capital Corporation (the "**Programme**").

The Final Terms for the Notes contain the final terms of the relevant series of Notes. The Final Terms of the Notes must be read in conjunction with the Information Memorandum prepared in connection with the Programme dated 16 May 2025 (the "Information Memorandum"), which constitutes a base prospectus for the purposes of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

To view the full documents, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/5821J_1-2025-5-21.pdf

http://www.rns-pdf.londonstockexchange.com/rns/5821J 2-2025-5-21.pdf

A copy of the Final Terms in respect of each series will be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further information, please contact:

Unilever PLC

Unilever House

100 Victoria Embankment

London EC4Y 0DY

T: +44 (0) 20 7822 5252 F: +44 (0) 20 7822 5464

This announcement does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Final Terms (when read together with the Information Memorandum) may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Information Memorandum) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms and the Information Memorandum is not addressed. Prior to relying on the information contained in the Final Terms or the Information Memorandum, you must ascertain from the Information Memorandum whether or not you are one of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

Forward-looking statements

This announcement may contain forward-looking statements. Words such as 'expects', 'anticipates', 'intends', 'believes' or the negative of these terms and other similar expressions of future performance or results and their negatives are intended to identify such forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Unilever Group. They are not historical facts, nor are they guarantees of future performance. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.

¹ Inilever Canital Compration - LEL MYF1DAS6G5WY7PRWCLI78

Officeor Capital Corporation - Element 15/100000 11/1 1/11/20070

 2 Unilever PLC - LEI 549300MKFYEKVRWML317

³Unilever United States, Inc. - LEI 549300H6H8BAYLUOGZ71

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PFTFIFFTEIILFIE